Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 477

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer

Open access
Matei, Daniela, Filiaci, Virginia, Randall, Marcus E., Mutch, David, Steinhoff, Margaret M., DiSilvestro, Paul A., Moxley, Katherine M., Kim, Yong M., Powell, Matthew A., O’Malley, David M., Spirtos, Nick M., Small, William, Tewari, Krishnansu S., Richards, William E., Nakayama, John, Matulonis, Ursula A., Huang, Helen Q., Miller, David S.·2019·New England Journal of Medicine

Abstract

BACKGROUND: Stage III or IVA endometrial cancer carries a significant risk of systemic and locoregional recurrence. METHODS: In this randomized phase 3 trial, we tested whether 6 months of platinum-based chemotherapy plus radiation therapy (chemoradiotherapy) is associated with longer relapse-free survival (primary end point) than six cycles of combination chemotherapy alone in patients with stage III or IVA endometrial carcinoma. Secondary end points included overall survival, acute and chronic toxic effects, and quality of life. RESULTS: Of the 813 patients enrolled, 736 were eligible and were included in the analysis of relapse-free survival; of those patients, 707 received the randomly assigned intervention (346 received chemoradiotherapy and 361 received chemotherapy only). The median follow-up period was 47 months. At 60 months, the Kaplan-Meier estimate of the percentage of patients alive and relapse-free was 59% (95% confidence interval [CI], 53 to 65) in the chemoradiotherapy group and 58% (95% CI, 53 to 64) in the chemotherapy-only group (hazard ratio, 0.90; 90% CI, 0.74 to 1.10). Chemoradiotherapy was associated with a lower 5-year incidence of vaginal recurrence (2% vs. 7%; hazard ratio, 0.36; 95% CI, 0.16 to 0.82) and pelvic and paraaortic lymph-node recurrence (11% vs. 20%; hazard ratio, 0.43; 95% CI, 0.28 to 0.66) than chemotherapy alone, but distant recurrence was more common in association with chemoradiotherapy (27% vs. 21%; hazard ratio, 1.36; 95% CI, 1.00 to 1.86). Grade 3, 4, or 5 adverse events were reported in 202 patients (58%) in the chemoradiotherapy group and 227 patients (63%) in the chemotherapy-only group. CONCLUSIONS: Chemotherapy plus radiation was not associated with longer relapse-free survival than chemotherapy alone in patients with stage III or IVA endometrial carcinoma. (Funded by the National Cancer Institute; ClinicalTrials.gov number, NCT00942357.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1813181

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 477

Metadata

Authors
Matei, D., Filiaci, V., Randall, M. E., Mutch, D., Steinhoff, M. M., DiSilvestro, P. A., Moxley, K. M., Kim, Y. M., Powell, M. A., O’Malley, D. M., Spirtos, N. M., Small, W., Tewari, K. S., Richards, W. E., Nakayama, J., Matulonis, U. A., Huang, H. Q., & Miller, D. S.
Venue
New England Journal of Medicine
Published
2019-06-13
Volume
380
Issue
24
Pages
2317-2326
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2949349304
Cited by
477
References
18
FWCI
56.26
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer. https://app.cochat.ai/papers/10.1056/nejmoa1813181
The paper
Matei, D., Filiaci, V., Randall, M. E., Mutch, D., Steinhoff, M. M., DiSilvestro, P. A., Moxley, K. M., Kim, Y. M., Powell, M. A., O’Malley, D. M., Spirtos, N. M., Small, W., Tewari, K. S., Richards, W. E., Nakayama, J., Matulonis, U. A., Huang, H. Q., & Miller, D. S. (2019). Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1813181

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.